Tumors grown in vivo are usually endowed with the ability to escape the host's immunological surveillance via various mechanisms. First, tumor cells produce immunosuppressive factors by which they inhibit each process involved in the induction of antitumor cell-mediated immunity. For example, transforming growth factor-β (TGF-β) inhibits the differentiation and proliferation of cytotoxic T lymphocytes (CTL) and the production of interleukin 2 (IL-2) and IL-12.
1-3) IL-10 inhibits cytokine production by Th1 cells and the antigen presentation capacity of monocytes via downregulation of major histocompatibility complex (MHC) class II expression. [4] [5] [6] Prostaglandin E2 (PGE2) inhibits IL-2 production, IL-2 responses and MHC class II expression. 7, 8) Some tumor cells suppress the differentiation of dendritic cells, potent antigen-presenting cells, by secreting vascular endothelial growth factor (VEGF). 9) Second, tumors are frequently defective in presenting immunogenicity, having low expression of MHC class I, class II or costimulatory molecules such as B7. Therefore, it is suggested that they cause decreased recognition of antigens by T cells and the induction of peripheral tolerance. 10) Furthermore, it is reported that abnormality of the ζ chain which constitutes T cell receptor (TCR) complex causes dysfunction of effector T cells themselves in a tumor-bearing host. 10) Accordingly, a method of enhancing the immunogenicity of tumor cells or stimulating the host's antitumor immunity will be required to overcome the escape of tumor cells from the host's immunological surveillance.
Tumor necrosis factor-α (TNF-α) and IL-12, which are both potent antitumor cytokines, are known to be involved in antitumor immunological surveillance of the host via different mechanisms. TNF-α possesses such immunostimulatory activities as enhancement of macrophage, natural killer/lymphokine-activated killer (NK/LAK) and CTL activities 11, 12) and the antigen-presenting capacity of dendritic cells. 13) We previously reported that Meth-A cells transfected with TNF gene showed reduced tumorigenicity and exhibited therapeutic vaccination effects against preexisting tumors. 14) We have also found that an important aspect of the mechanisms behind these antitumor effects is augmentation of the cytotoxic effects of such killer cells as CTL and LAK and enhancement of MHC class I expression on tumor cells. Moreover, we demonstrated that TNF gene transfection of tumor cells freshly isolated from the ascitic fluids of patients with gastrointestinal cancers enhanced the expression of MHC class I and/or intercellular adhesion molecule-I (ICAM I), and we suggested that this would be involved in augmentation of the killer activity of tumor-infiltrating lymphocytes (TIL) induced by coculturing with autologous tumor cells transfected with TNF gene. 15) On the other hand, IL-12 is a cytokine which potently induces Th1-type cell-mediated immunity 16) and enhances the activities of natural killer T (NKT), 17) NK/ LAK 18) and CTL. 19) Through these immunostimulatory actions, IL-12 is reported to exert potent antitumor and antimetastatic effects via systemic administration 20, 21) or upon local production induced by cancer vaccines. 22) In the present study, we investigated the feasibility of cancer vaccines using Meth-A cells double-transfected with TNF-α and IL-12 genes in a murine model, in the expectation that synergistic or supplementary actions of both cytokines would broadly stimulate the host's immune network.
MATERIALS AND METHODS

Cell lines and culture
The 3-methyl-cholanthreneinduced murine fibrosarcoma cell line, Meth-A (M0), murine colon adenocarcinoma cell line, colon 26 and murine lymphoma cell line, YAC-1, were obtained from the American Type Culture Collection (ATCC). These cell lines were cultured in RPMI 1640 (GIBCO, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (Flow Laboratories, North Ryde, Australia), 100 U/ ml penicillin and 100 mg/ml streptomycin, and maintained at 37°C under 5% CO 2 . Each transfectant derived from M0 (see below) was also cultured in the same way. Animals Female BALB/c mice were purchased from Charles River Japan (Tokyo) and fed in a specific pathogen-free environment. Only mice older than 8 weeks were used in this experiment. TNF gene transfection The human TNF expression vector (pLJ-TNF) was constructed by inserting human TNF cDNA derived from pcDV-TNF 23) into a unique BamHI site of the retroviral vector pLJ. 24) Cell lines that produce modified viruses had been previously established. 14) Meth-A cells (M0) were incubated with a viral solution of virusproducing clones (pLJ-TNF introduced) in the presence of 8 µg/ml of polybrene for 2 h at 37°C. TNF gene transfectants (M-TNF) were selected by incubation with 400 µg/ ml G418 (Life Technologies, Inc., Gaithersburg, MD) for 14 days. LacZ gene-transfected cells were produced as mock transfectants using the same procedures. IL-12 gene transfection The retroviral vector TFG-mIL-12-neo was generously provided by Dr. Tahara (University of Pittsburgh). 22 6 ) were inoculated into BALB/c mice as described above. One week later, the spleen was removed aseptically and splenocytes were harvested. Splenocytes (5×10 6 ) were cocultured with M0 cells (1×10 5 ) pretreated for 1 h with mitomycin C (MMC) (100 µg/ml) in 2 ml of RPMI 1640 medium, in a 24-well plate, followed by addition of 100 JRU/ml IL-2 on day 2 of culture. Five days after incubation, stimulated splenocytes were collected for evaluation of their killing activity. Cytotoxicity assay M0 and YAC-1 cells (1×10 5 ) radiolabeled with 51 Cr were incubated with killer cells obtained from MLTC in various ratios in a 96-well plate. After incubation for 4 h, the plate was centrifuged and the radioactivity in the supernatant was counted using a γ-counter. Percent specific lysis was calculated as follows: % specific lysis=(mean cpm from test supernatants−mean cpm from supernatants of target cells alone (spontaneous release))/ (mean cpm after target cell lysis with lysis buffer (total release)−spontaneous release) ×100.
A blocking experiment was also conducted with anti-MHC class I monoclonal antibody (H-2K d , Meiji Nyugyo) to clarify the involvement of CTL in the cytotoxicity of these killer cells against M0.
51 Cr-labeled parental cells were pretreated with a saturating amount of the monoclonal Ab at 4°C for 1 h, washed twice with phosphatebuffered saline (PBS) and then used in the cytotoxicity assay.
RESULTS
Production of TNF and IL-12 by the gene transfectants TNF or IL-12 production in the culture medium of transfectants was measured by ELISA (Table I) In mice inoculated with double transfectants with both genes (M-TNF/IL-12), complete regression was obtained in 100% of mice. This antitumor effect was inhibited by treatment with anti-CD8 antibody (Fig. 2) . The in vitro growth rate was almost the same for parental cells and transfectants (data not shown). Induction of specific immunity against rechallenged tumors Parental cells (M0) or colon 26 cells (1×10 6 ) were inoculated into the opposite flank of mice which had undergone complete regression of previously inoculated TNF or IL-12 gene-transfected Meth-A cells (M-TNF or M-IL-12). Colon 26 tumor grew progressively, whereas M0 tumor was completely rejected after forming a palpable tumor, indicating the induction of tumor-specific immunity (data not shown). Moreover, we also observed the induction of tumor-specific immunity with double transfectants (M-TNF/IL-12) (Fig. 3) . by anti-class I monoclonal antibody. In addition, cytotoxicity of killer cells against YAC-1 cells was also enhanced in mice inoculated with double transfectants compared to either of the single transfectants.
DISCUSSION
In the present study, we attempted to obtain efficient antitumor effects by transducing the genes of two antitumor cytokines which have different mechanisms into tumor cells, and utilizing them as a vaccine to broadly stimulate the antitumor immune network. Double transfection with TNF-α and IL-12 genes apparently induced synergistic antitumor effects, and these effects were supported by cytotoxicity assay. Splenocytes induced from mice bearing double transfectants showed more potent cytotoxicity against the parental cells compared to those from mice bearing single transfectants. It was clear that Meth-A cell-specific CTL was critically involved in this cytotoxicity, as it was blocked by anti-MHC class I antibody, and its antitumor effect was inhibited by anti-CD8 antibody. Moreover, rechallenged Meth-A cells, but not colon 26 cells, were rejected. However, as splenocytes induced from mice bearing double transfectants also showed considerable cytotoxicity against YAC-1 cells, NK in addition to CTL was suggested to play an important role in this cytotoxicity. In fact, TNF-α and IL-12 are reported to synergistically enhance NK activity. 25) There seem to be two possible mechanisms for the enhancement of this killing activity. One is that the two cytokines secreted from double transfectants induced additive or synergistic activation of effector cells, such as CTL and LAK. The other possibility is that the expression of tumor surface molecules was enhanced by gene transfection. We previously reported that the transfection of TNF gene could enhance the expression of MHC class I and ICAM I on tumor cells. 14, 15) Then, we examined the expression of surface antigens on double transfectants by flow cytometry. Transfection with IL-12 gene enhanced MHC class I expression and furthermore, slightly enhanced the expression of MHC class II and B7.1. On the other hand, double transfection with TNF and IL-12 genes significantly enhanced the expression of MHC class I, class II and B7.1 compared to the transfection with either gene alone. Also, because tumor-related antigenic peptides such as GP110 have been identified on Meth-A cells, 26) synergistic effects might be caused by upregulation of tumor antigens. We conducted similar experiments using mice inoculated with a murine melanoma cell line, B16. The expression of MHC class I, class II or B7.1 was enhanced on double transfectants (B-TNF/IL-12) compared to that on single transfectants with either gene. Nevertheless, no synergistic antitumor effects were observed compared with single transfectants (data not shown). This is presumably due to inherently low expression of tumor antigens, leading to insufficient induction of CTL.
On the other hand, it has been demonstrated that IL-12 activates not only CTL, 19) but also NKT. 17) As NKT exerts potent antimetastatic effects, in the case of B-16 cells, when we use the model of metastatic tumors, it is possible 
